Daily Newsletter

21 November 2023

Daily Newsletter

21 November 2023

NVIDIA and LTTS team up to bring Gen AI to endoscopy imaging

The two companies will focus their efforts on developing software-defined architectures for endoscopy-oriented medical devices.

Robert Barrie November 20 2023

Tech giant NVIDIA will provide some of its artificial intelligence (AI) platforms to L&T Technology Services Limited (LTTS), after the companies entered a collaboration to develop software to support and enhance medical imaging.

The two companies will focus on developing software-defined architectures for endoscopy-oriented medical devices, according to a 20 November press release by LTTS.

Shares in LTTS rose following the announcement, closing 1.7% higher on the National Stock Exchange of India on 20 November compared to a pre-announcement market close on 17 November.

India-headquartered LTTS, whose sector interests include medical, automotive, and semiconductor engineering amongst others, said that the new software architecture helps reduce noise whilst enhancing contrast, edge, texture, and colour. Adding AI and machine learning models also help detect polyps – abnormal growths often found during colonoscopies, the company said.

NVIDIA will supply its Holoscan software and NVIDIA IGX Orin hardware, a popular AI technology used in the medical imaging sector.

LTTS CEO Amit Chadha said the collaboration would help “push the boundaries” of medical imaging potential, adding that combining Holoscan and NVIDIA IGX Orin “accelerates the development of AI-powered medical imaging solutions by enhancing image quality and real-time clinical decision-making support”.

AI is making waves in medical imaging – providing the framework for software that automates part of the imaging clinical workflow. This supports healthcare professionals by reducing workload.

Medical imaging is a major driver of AI’s growth in healthcare – a 2023 report by GlobalData predicts that global revenue for AI platforms across healthcare will reach $18.8bn by 2027.

However, some in the industry have called for more solid digital foundations in healthcare systems if AI’s implementation is to succeed in the long term.

Can Generative AI transform the medical devices industry?

The healthcare, pharma, and medical devices industries are often risk-averse compared to other sectors when adopting new technologies. However, mainly due to COVID-19, these sectors have witnessed an acceleration in digital transformation, which has improved efficiencies and enhanced patient outcomes. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close